Boston Scientific’s Lotus TAVR Gets Boost From REPRISE II And UK Series
This article was originally published in Clinica
Boston Scientific’s Lotus transcatheter aortic valve replacement system demonstrated favorable outcomes in the REPRISE II trial and a 228-case series in the UK.
You may also be interested in...
OUS Approvals Analysis: BSX, Edwards Score New CE Marks In TAVR Battlefield; Chinese DES Advances In Asia
September's list of devices approved outside the US include a new transcatheter aortic valve in Europe, two orthopedic devices and a gynecology device in Australia, and a drug-eluting stent in Pakistan.
The company is recalling unused valves made before March 2016, which use a component that may break during deployment. Three patients have died of hemorrhage caused by the breakage.
The 500-patient REPAIR MR trial will evaluate Abbott’s MitraClip mitral valve repair device in patients who would face moderate risk during open heart surgery. MitraClip is currently approved only for patients who are not surgical candidates.